Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 8/20 | 0.52 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.52 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.52 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.47 |
| ▸ | GNPAT | O15228 | 1/20 | 0.45 |
| ▸ | FNTA | P49354 | 2/20 | 0.43 |
| ▸ | FNTB | P49356 | 2/20 | 0.43 |
| ▸ | GGH | Q92820 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4572551 | 0.86 | FOLH1 (0.69) | FOLH1NAALAD2RIMKLAGNPATGGH | |
| SCHEMBL15451427 | 0.85 | GNPAT (0.58) | FOLH1NAALAD2RIMKLANOD1GNPAT | |
| SCHEMBL17776319 | 0.85 | NOD1 (0.65) | FOLH1NAALAD2RIMKLANOD1GNPAT | |
| SCHEMBL14683450 | 0.85 | NOD1 (0.47) | FOLH1NAALAD2RIMKLANOD1GNPAT | |
| SCHEMBL7607007 | 0.85 | NOD1 (0.51) | FOLH1NAALAD2RIMKLANOD1GNPAT | |
| SCHEMBL10523153 | 0.85 | FOLH1 (0.62) | FOLH1NAALAD2RIMKLANOD1GNPAT | |
| SCHEMBL28385121 | 0.85 | FOLH1 (0.62) | FOLH1NAALAD2RIMKLANOD1GNPAT | |
| SCHEMBL28385118 | 0.85 | FOLH1 (0.62) | FOLH1NAALAD2RIMKLANOD1GNPAT | |
| SCHEMBL14478726 | 0.83 | NOD1 (0.54) | FOLH1NAALAD2RIMKLANOD1GNPAT | |
| SCHEMBL15451406 | 0.83 | NOD1 (0.54) | FOLH1NAALAD2RIMKLANOD1GNPAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129343-B2 | Acylated GLP-1 compounds | NOVO NORDISK A/S (DK) | 2012-03-06 | — | — | US | disclosed |
| US-20090156478-A1 | Acylated GLP-1 Compounds | NOVO NORDISK A/S (DK) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156478-A1 | Acylated GLP-1 Compounds | GLP1R, GIPR, GCGR | FOLH1 450/4885NAALAD2 112/4885RIMKLA 742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.